$Emergent BioSolutions (EBS.US)$Emergent BioSolutions- Deal to Resolve Claims From Manufacturing Services Deal for J&J's Investigational Sars-Cov-2 Vaccine, Ad26.cov2-S, Recombinant! Jannsen will pay 50 million on or before July 31 2024!
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Jaguar8 : Good for EBS
Trytosaveabit OP Jaguar8 : Yup! That’s will help the bottom line! Hehehe